Financials
| 1st Quarter Results | Apr. 30, 2025 |
| GSK plc 2024 Annual Report on Form 20-F | Mar. 03, 2025 |
| GSK publishes Annual Report 2024 | Feb. 27, 2025 |
| 2024 Annual Financial Report | Feb. 27, 2025 |
| Final Results | Feb. 05, 2025 |
| 3rd Quarter Results | Oct. 30, 2024 |
| 2nd Quarter Results | Jul. 31, 2024 |
Proxies
| Result of AGM | May. 07, 2025 |
| GSK Proxy Form 2025 | Mar. 24, 2025 |
| GSK AGM Notice 2025 | Mar. 24, 2025 |
| Notice of AGM | Mar. 24, 2025 |
| Result of AGM | May. 08, 2024 |
| GSK Proxy Form 2024 | Mar. 25, 2024 |
| GSK AGM Notice 2024 | Mar. 25, 2024 |
Ownership Update
| Transaction in Own Shares | Jul. 11, 2025 |
| Transaction in Own Shares | Jul. 10, 2025 |
| Transaction in Own Shares | Jul. 09, 2025 |
| Transaction in Own Shares | Jul. 08, 2025 |
| Transaction in Own Shares | Jul. 07, 2025 |
| Transaction in Own Shares | Jul. 04, 2025 |
| Transaction in Own Shares | Jul. 03, 2025 |
Announcements
| GSK completes acquisition of efimosfermin for SLD | Jul. 07, 2025 |
| Total Voting Rights | Jul. 01, 2025 |
| Director Declaration | Jun. 24, 2025 |
| Replacement RNS: Linerixibat file accepted by EMA | Jun. 23, 2025 |
| GSK Submits Arexvy for adults 18+ with EMA | Jun. 23, 2025 |
| Arexvy filed in Japan for 18-49 at increased risk | Jun. 20, 2025 |
| GSK submits Arexvy for adults 18+ with EMA | Jun. 13, 2025 |
Prospectuses
| GSK plc;GLAXOSMITHKLINE CAPITAL PLC;GSK Capital B.V.;GSK Capital K.K - Base prospectus (debt) | Sep. 07, 2022 |